These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 37483629)

  • 1. Engineering cytokines for cancer immunotherapy: a systematic review.
    Fu Y; Tang R; Zhao X
    Front Immunol; 2023; 14():1218082. PubMed ID: 37483629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering Strategies for Immunomodulatory Cytokine Therapies - Challenges and Clinical Progress.
    Pires IS; Hammond PT; Irvine DJ
    Adv Ther (Weinh); 2021 Aug; 4(8):. PubMed ID: 34734110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine engineering for targeted cancer immunotherapy.
    Bonati L; Tang L
    Curr Opin Chem Biol; 2021 Jun; 62():43-52. PubMed ID: 33684633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
    Xiang J
    Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in engineering and delivery strategies for cytokine immunotherapy.
    Bohmer M; Xue Y; Jankovic K; Dong Y
    Expert Opin Drug Deliv; 2023 May; 20(5):579-595. PubMed ID: 37104673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine-based Cancer Immunotherapy: Challenges and Opportunities for IL-10.
    Rallis KS; Corrigan AE; Dadah H; George AM; Keshwara SM; Sideris M; Szabados B
    Anticancer Res; 2021 Jul; 41(7):3247-3252. PubMed ID: 34230118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.
    Young PA; Morrison SL; Timmerman JM
    Semin Oncol; 2014 Oct; 41(5):623-36. PubMed ID: 25440607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation cytokines for cancer immunotherapy.
    Xue D; Hsu E; Fu YX; Peng H
    Antib Ther; 2021 Apr; 4(2):123-133. PubMed ID: 34263141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming the limitations of cytokines to improve cancer therapy.
    Di Trani CA; Cirella A; Arrizabalaga L; Fernandez-Sendin M; Bella A; Aranda F; Melero I; Berraondo P
    Int Rev Cell Mol Biol; 2022; 369():107-141. PubMed ID: 35777862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing cytokines and chemokines for cancer therapy.
    Propper DJ; Balkwill FR
    Nat Rev Clin Oncol; 2022 Apr; 19(4):237-253. PubMed ID: 34997230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity.
    Li Z; Hu L; Wang Y; Liu Q; Liu J; Long H; Li Q; Luo L; Peng Y
    Front Immunol; 2024; 15():1455019. PubMed ID: 39290693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localized Interleukin-12 for Cancer Immunotherapy.
    Nguyen KG; Vrabel MR; Mantooth SM; Hopkins JJ; Wagner ES; Gabaldon TA; Zaharoff DA
    Front Immunol; 2020; 11():575597. PubMed ID: 33178203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoengineering approaches for cytokine therapy.
    Mansurov A; Lauterbach A; Budina E; Alpar AT; Hubbell JA; Ishihara J
    Am J Physiol Cell Physiol; 2021 Aug; 321(2):C369-C383. PubMed ID: 34232748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facts and Hopes on Chimeric Cytokine Agents for Cancer Immunotherapy.
    Ren Z; Zhang X; Fu YX
    Clin Cancer Res; 2024 May; 30(10):2025-2038. PubMed ID: 38190116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering interferons and interleukins for cancer immunotherapy.
    Holder PG; Lim SA; Huang CS; Sharma P; Dagdas YS; Bulutoglu B; Sockolosky JT
    Adv Drug Deliv Rev; 2022 Mar; 182():114112. PubMed ID: 35085624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments.
    Müller D
    BioDrugs; 2014 Apr; 28(2):123-31. PubMed ID: 24018469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.
    Neri D
    Cancer Immunol Res; 2019 Mar; 7(3):348-354. PubMed ID: 30824549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.